Skip to main content

C V Starr & Co Inc

SEC CIK
0001340459
Latest filing
Aug 11, 2026

The latest 13F from C V Starr & Co Inc covers Q2 2026 (filed Aug 11, 2026): 5 long positions worth $187.3M. The top 10 holdings make up 100.0% of the portfolio, and the largest is SPDR Gold Trust (GLD) at 49.4%. Livermore has 18 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
0
Added
0
Reduced
0
Sold out
0

Top 5 holdings

Share of this quarter's portfolio value

  1. GLDSPDR Gold Trust
    49.4%$92.6MHistory
  2. iShares Tr46435G326
    18.0%$33.7M
  3. iShares Core S&P Small Cap ETF464287804
    15.9%$29.7M
  4. Vanguard Admiral FDS Inc921932885
    15.8%$29.7M
  5. CELUCelularity Inc
    0.8%$1.58MHistory

Share of portfolio

Each position's share of portfolio value

  1. GLD49.4%
  2. iShares Tr18.0%
  3. iShares Core S&P Small Cap ETF15.9%
  4. Vanguard Admiral FDS Inc15.8%
  5. CELU0.8%

Biggest buys

New and added positions, by estimated amount bought

None this quarter.

Largest weight increases

New and added positions, by percentage points of the portfolio gained

None this quarter.

Biggest sells

Reduced and sold-out positions, by estimated amount sold

None this quarter.

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

None this quarter.

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$187.3M
−$4.47M (−2.3%) vs. prior quarter
Positions
5
0 vs. prior quarter
Top 10 concentration
100.0%
Top 10 as share of value
Turnover
0.0%
Q2 2026, one quarter
Average holding period
6.0 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

18 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $216.6M (Q3 2025)

Q1 2021: $4.64MQ2 2021: $5.16MQ3 2021: $4.93MQ4 2021: $27.1MQ1 2022: $71.4MQ2 2022: $29.2MQ3 2022: $21.0MQ4 2022: $12.4MQ1 2023: $7.84MQ2 2023: $7.96MQ3 2023: $5.49MQ4 2024: $128.1MQ1 2025: $129.8MQ2 2025: $192.4MQ3 2025: $216.6MQ4 2025: $182.0MQ1 2026: $191.8MQ2 2026: $187.3M
Q1 2021Q2 2026
13F filings of C V Starr & Co Inc by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 11, 20265$187.3MGLDiShares TriShares Core S&P Small Cap ETFvs. Q1 2026SEC
Q1 2026May 11, 20265$191.8MGLDiShares TrVanguard Admiral FDS Incvs. Q4 2025SEC
Q4 2025Feb 9, 20265$182.0MGLDiShares TrVanguard Admiral FDS Incvs. Q3 2025SEC
Q3 2025Nov 12, 20255$216.6MGLDiShares TrVanguard Admiral FDS Incvs. Q2 2025SEC
Q2 2025Aug 8, 20255$192.4MGLDiShares TrVanguard Admiral FDS Incvs. Q1 2025SEC
Q1 2025May 13, 20255$129.8MGLDiShares Core MSCI Eafe ETFMDYvs. Q4 2024SEC
Q4 2024Feb 12, 20256$128.1MGLDiShares Core MSCI Eafe ETFVanguard Morningstar Mid-Cap ETF–SEC
Q3 2023Nov 14, 20232$5.49MAMZNCELUvs. Q2 2023SEC
Q2 2023Aug 14, 20232$7.96MCELUAMZNvs. Q1 2023SEC
Q1 2023May 3, 20232$7.84MCELUAMZNvs. Q4 2022SEC
Q4 2022Feb 13, 20232$12.4MCELUAMZNvs. Q3 2022SEC
Q3 2022Oct 31, 20222$21.0MCELUAMZNvs. Q2 2022SEC
Q2 2022Aug 12, 20222$29.2MCELUAMZNvs. Q1 2022SEC
Q1 2022May 11, 20222$71.4MCELUAMZNvs. Q4 2021SEC
Q4 2021Jan 27, 20222$27.1MCELUAMZNvs. Q3 2021SEC
Q3 2021Nov 2, 20211$4.93MAMZNvs. Q2 2021SEC
Q2 2021Jul 19, 20211$5.16MAMZNvs. Q1 2021SEC
Q1 2021Apr 21, 20211$4.64MAMZN–SEC

13D and 13G filings

Companies where C V Starr & Co Inc reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

C V Starr & Co Inc does not currently report owning 5% or more of any company.

Latest filings

1 filing on file made by C V Starr & Co Inc or listing it as a reporting person, newest first.

Schedule 13D and 13G filings by C V Starr & Co Inc
CompanyFiled (ET)FormStakeChangeEvent dateFiling
CELUCelularity IncFeb 13, 202313GOld format–New–SEC